Entera Bio (ENTX)
(Delayed Data from NSDQ)
$1.71 USD
0.00 (0.00%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.71 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Entera Bio Ltd. [ENTX]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
EB612 Phase 1 Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
Positive EB612 PK Data Slated for ENDO Presentation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
1Q24 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
Multiple Recent Milestones; 2023 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
EB613 Interim Phase 1 Comparative PK Data; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
Bone Mineral Density Endpoint Qualification Plan Sent to FDA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
Peptide Oral Delivery Research Collaboration Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
EB613 Targeting Green Field Opportunity; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
EB613 Progressing; 1Q23 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
FDA Type D Guidance Received; 2022 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
FDA Type D Responses Imminent; NASDAQ Compliance Regained; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
Competitor Submissions Provide Potential EB612 Tailwind; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
EB613 Pivotal Trial Starting Next Year; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
FDA Type C Meeting Confirms EB613 Pivotal Development Path; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
KOL Webinar Underscores EB613 Value Proposition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
Transforming Injectable Drugs Into Pills; Initiating at Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entera Bio Ltd.
Industry: Medical - Biomedical and Genetics
|